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Abstract
Background
One million neonates die each year in low- and middle-income countries because of neona-
tal sepsis; group B Streptococcus (GBS) and Escherichia coli are the leading causes. In
sub-Saharan Africa, epidemiological data on vaginal GBS and E. coli carriage, a prerequi-
site for GBS and E. coli neonatal sepsis, respectively, are scarce but necessary to design
and implement prevention strategies. Therefore, we assessed vaginal GBS and E. coli car-
riage rates and risk factors and the GBS serotype distribution in three sub-Saharan
countries.
Methods
A total of 430 women from Kenya, Rwanda and South Africa were studied cross-sectionally.
Vaginal carriage of GBS and E. coli, and GBS serotype were assessed using molecular
techniques. Risk factors for carriage were identified using multivariable logistic regression
analysis.
Results
Vaginal carriage rates in reference groups from Kenya and South Africa were 20.2%
(95% CI, 13.7–28.7%) and 23.1% (95% CI, 16.2–31.9%), respectively for GBS; and 25.0%
(95% CI, 17.8–33.9%) and 27.1% (95% CI, 19.6–36.2%), respectively for E. coli. GBS sero-
types Ia (36.8%), V (26.3%) and III (14.0%) were most prevalent. Factors independently
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associated with GBS and E. coli carriage were Candida albicans, an intermediate vaginal
microbiome, bacterial vaginosis, recent vaginal intercourse, vaginal washing, cervical
ectopy and working as a sex worker. GBS and E. coli carriage were positively associated.
Conclusions
Reduced vaginal GBS carriage rates might be accomplished by advocating behavioral
changes such as abstinence from sexual intercourse and by avoidance of vaginal washing
during late pregnancy. It might be advisable to explore the inclusion of vaginal carriage of C.
albicans, GBS, E. coli and of the presence of cervical ectopy in a risk- and/or screening-
based administration of antibiotic prophylaxis. Current phase II GBS vaccines (a trivalent
vaccine targeting serotypes Ia, Ib, and III, and a conjugate vaccine targeting serotype III)
would not protect the majority of women against carriage in our study population.
Introduction
One million children die each year in low- and middle-income countries in the first 4 weeks of
life because of neonatal sepsis [1]. Early-onset neonatal sepsis (EOS), occurring in the first
week of life, accounts for approximately 80% of cases, and is caused by bacteria that are trans-
mitted vertically from the genital tract of the mother to infant before or during delivery [2].
Late-onset neonatal sepsis (LOS) occurs between week 1 and month 2 to 3 of life and may be
caused by bacteria acquired vertically or horizontally [3]. Because the transfer of a single spe-
cies from the maternal genitourinary tract to the neonate before or during delivery is a prereq-
uisite for EOS [4], there are unique opportunities for prevention of EOS.
At present, Streptococcus agalactiae (Group B Streptococcus, GBS) and Escherichia coli are
the leading causes of EOS worldwide [5]. Furthermore, GBS and E. coli are associated with pre-
term birth, very-low-birth-weight delivery and puerperal sepsis [6, 7], which cause substantial
morbidity and mortality in sub-Saharan Africa (SSA) [2, 8, 9].
To prevent EOS, efforts have been focusing mainly on GBS and high-income countries,
based on two strategies, namely the screening- or risk-based administration of intrapartum
antibiotic prophylaxis (IAP) and the development of vaccines [10].
IAP has been shown to reduce the incidence of GBS EOS from 1.7/1000 to 0.6/1000 in the
US [11], but is not effective against E. coli EOS, LOS, and adverse perinatal outcomes related to
GBS [12, 13]. Furthermore, according to the current universal guidelines (Centers for Disease
Control and Prevention, CDC), IAP should be administered to women found positive for GBS
at 35–37 weeks of gestation [14]. However, these guidelines are not followed in most health-
care facilities in low-income countries. The use of intravaginal washes with chlorhexidine (a
wide-spectrum microbicide) during labour and neonatal wipes with chlorhexidine, has been
explored in low- and middle-income countries, but is unlikely to prevent vertically acquired
neonatal infections in any setting or population [4].
Most GBS vaccines under development aim at eliciting protective antibodies against capsu-
lar polysaccharides (CPS), the most important GBS virulence factor of which ten antigenically
distinct CPS are known [10], and are attractive as some of the IAP-related problems may be
circumvented [10]. However, these vaccines might not be effective in low-income countries
because of different serotype distribution [15].
Although SSA has the highest rates of neonatal sepsis mortality worldwide, epidemiological data
on vaginal GBS and E. coli carriage are very limited but necessary to develop and implement pre-
vention strategies [16, 17]. Therefore, in this multi-country cross-sectional study, we assessed the
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vaginal GBS and E. coli carriage prevalence, risk factors for GBS and E. coli carriage, and GBS sero-
type distribution in populations from three countries: Kenya, Rwanda and South Africa.
Patients and Methods
Study design and population
In 2010–2011, we conducted a multi-country follow-up study entitled ‘‘Characterisation of novel
microbicide safety biomarkers in East and South Africa”. The main aim of that project was to
characterise the vaginal microbiome and the cervicovaginal mucosal immune system in African
women and to assess changes of these over time [18–21]. In that study, 430 women were recruited
at three study sites, i.e. the International Centre for Reproductive Health Kenya (ICRHK) in
Mombasa, Kenya (170 women); the non-governmental organisation Rinda Ubuzima (RU) in
Kigali, Rwanda (60 women), and theWits Reproductive Health and HIV Institute (Wits RHI) in
Johannesburg, South Africa (SA) (200 women). The women were recruited into 6 predefined
study groups: a reference group of 219 women (adult, non-pregnant, HIV-negative women at
average risk of HIV), 60 pregnant women (up to 14 weeks of gestational age as determined by
abdominal ultrasound at recruitment), 60 adolescent girls (16–17 years), 31 HIV-negative women
engaging in vaginal practices (usage of cloth, lemon juice, or detergents to clean, dry or tighten
the vagina on a regular basis), 30 self-acknowledged female sex workers (FSW), and 30 HIV-posi-
tive women (on antiretroviral treatment for at least 6 months, asymptomatic and with a CD4
count of more than 350 cells/μl) (Table 1). Participants were eligible for inclusion if they were in
good physical and mental health, able and willing to participate in the study as required by the
protocol, able and willing to give written informed consent (including written parental or guard-
ian consent for adolescents). Women were excluded if they had never had penetrative vaginal
intercourse, if they had a history of hysterectomy or other genital tract surgery in the three
months prior to the screening visit, if external and/or internal genital warts were found, if they
were enrolled in HIV prevention trials involving investigational products, if they were less than 6
months post-partum at the time of enrolment, if they were HIV-positive (unless for inclusion in
the HIV-positive women group), or if they were pregnant (unless for inclusion in the pregnant
women group). The study population, followed up for approximately eight months per person
over 8 visits, is described in detail by Jespers and coworkers [19].
The current study presents one of the tertiary objectives of the above mentioned study,
namely to document the vaginal carriage rates of the main pathogens associated with EOS
(GBS and E. coli) and the risk factors for their carriage. These analyses are based on the screen-
ing visit and the first visit (scheduled soon after the last day (day 9 +/- 2 days) of the menstrual
period) from the follow-up study.
Table 1. Study population and vaginal GBS and E. coli carriage rates.
City, Country Group n GBS prevalence % (95% CI) E. coli prevalence % (95% CI)
Mombasa, Kenya Reference group 110 20.2 (13.7–28.7) 25.0 (17.8–33.9)
Mombasa, Kenya Pregnant women 30 14.3 (5.7–31.5) 14.3 (5.7–31.5)
Mombasa, Kenya Adolescents 30 3.6 (0.6–17.7) 28.6 (15.3–47.1)
Kigali, Rwanda FSW 30 20.0 (9.5–37.3) 70.0 (52.1–83.3)
Kigali, Rwanda HIV+ women 30 0.0 (0.0–11.4) 20.0 (9.5–37.3)
Johannesburg, SA Reference group 109 23.2 (16.2–31.9) 27.1 (19.6–36.2)
Johannesburg, SA Pregnant women 30 10.0 (3.5–25.6) 33.3 (19.2–51.2)
Johannesburg, SA Adolescents 30 0.0 (0.0–11.4) 13.3 (5.3–29.7)
Johannesburg, SA Vaginal practices 31 25.8 (13.7–43.2) 30.0 (16.7–47.9)
doi:10.1371/journal.pone.0148052.t001
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Study procedures
At the screening visit, blood, vaginal, endocervical and urine samples were taken for diagnostic
testing of HIV, HSV-2, syphilis, Neisseria gonorrheae (NG), Chlamydia trachomatis (CT),
Trichomonas vaginalis (TV), urinary tract infection (UTI), pregnancy, cervical dysplasia (by
Pap smear), bacterial vaginosis (BV) (Amsel criteria), and vaginal candidiasis. Treatment was
provided according to national guidelines, voluntary HIV counseling was offered, and con-
doms were provided free-of-charge.
At visit 1, two sterile Copan flocked1 vaginal swabs (Copan Diagnostics, Inc., Murrieta,
CA), to be used for the molecular detection of GBS and E. coli, were brought into the vaginal
vault by the study clinician, rotated against the vaginal wall at the midportion of the vault,
gently dipped in the posterior fornix and carefully removed to prevent contamination with the
microbiome of the vulva and introitus. The swab heads were collected into two 1.5 ml cryovials,
labelled and immediately frozen at -80°C until shipment to the central laboratory at the Insti-
tute of Tropical Medicine (ITM, Antwerp, Belgium) using temperature-monitored dry ship-
pers filled with liquid nitrogen. One Amies swab (Copan Diagnostics, Inc.) for culturing was
taken in a likewise manner, placed in the Amies tube, and transported at 4°C in a temperature-
monitored cooler to the local laboratory, where it was processed immediately. At both visits,
women were interviewed during face-to-face interviews about their general and sexual health,
vaginal habits and sociodemographic characteristics. A physical examination including specu-
lum and bimanual pelvic examination was carried out by a clinician. At each visit, participants
were compensated for their time and transportation.
Diagnosis of genital infections
At the local laboratories, tests for HIV, HSV-2, syphilis, CT and NG were performed. For imme-
diate detection of Candida cells and hyphae, TV, and clue cells, wet mount microscopy was used.
For the purpose of this study, a commercially available TV InPouchTM system (BioMed Diagnos-
tics, White City, Oregon) was used. For this, a vaginal swab was inoculated according to the man-
ufacturer’s instructions and InPouch cultures were monitored on a daily basis. InPouch bags
with no growth at the end of five days were considered negative. BV diagnosed according to the
Amsel criteria was used for immediate treatment. For research, vaginal smears were made and
sent to ITM for Gram staining and Nugent scoring, a scoring system to diagnose BV. Briefly,
smears from vaginal swabs were prepared by rolling the swab onto a glass slide. Slides were air-
dried and fixed using 70% ethanol. For the Gram-staining at ITM, the fixed smear was covered
with crystal violet for 1 minute, washed with water, flooded with Lugol’s iodine for 1 minute,
washed with water, and then decolorized with acetone-alcohol for 2–3 seconds. The smears were
rinsed quickly under running water to stop the decolorisation and then counterstained with saf-
ranin for 1 minute. All reagents were from Becton Dickinson (BD). All smears were examined
microscopically with the 40X objective to check the staining and the distribution of the material,
and then assessed under oil immersion objective (1000x magnification) using the grading system
described by Nugent and co-workers [22]. The Nugent score is calculated by assessing for the
presence of Lactobacillus cell types, small Gram-variable coccobacilli, and curved Gram-variable
rods. A score of 0–3 is considered as normal (BV-negative); a score of 4–6 as an intermediate vag-
inal microbiome; and a score of 7–10 as BV-positive.
DNA extraction
For the molecular detection of GBS and E. coli, DNA extraction from the two Copan swabs of
each subject was carried out at ITM by thawing the swabs at room temperature for 30 minutes.
After adding 1200 μL of diluted PBS, each swab was gently vortexed for 15 seconds, and 1 mL
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of each swab suspension was pooled into a final volume of 2 mL. An aliquot of 250 μL was
extracted using the Abbott m24sp automated extraction platform (Abbott, Maidenhead, UK),
according to the manufacturer’s instructions, and 200 μl of eluted DNA—to be used in the
quantitative PCR (qPCR) assays—was stored at– 80°C.
For the construction of qPCR standard curves, DNA was extracted from overnight cultures
of S. agalactiae LMG 14694T on TSA + 5% sheep blood, E. coli ATCC 25922 grown on TSA
+ 5% sheep blood, and C. albicans ATCC 90028 grown on Sabouraud agar (all BD). All growth
was harvested from the plate and resuspended in 1 ml of saline. DNA of this suspension was
extracted using the High Pure PCR Template Preparation Kit (Roche Applied Science, Basel,
Switzerland) according to the manufacturer’s instructions.
For capsular genotyping of GBS, 1 ml of inoculated Lim Broth medium (see Microbiological
culturing) was used for DNA extraction using the High Pure PCR Template Preparation Kit
(Roche), according to the the manufacturer’s instructions.
Streptococcus agalactiae qPCR
To detect S. agalactiae in vaginal DNA extracts, a S. agalactiae specific qPCR was carried out,
using primers previously described [23]. The qPCR reactions for S. agalactiae were performed
in a final volume of 10 μl, containing 5 μl of LightCycler 4801 SYBR Green I Master (Roche),
0.5 μM of both forward primer Sip1 (5’-ATCCTGAGACAACACTGACA-3’) and reverse
primer Sip2 (5’-TTGCTGGTGTTTCTATTTTCA-3’), 0.3 μM of probe (5’- 6-FAM–ATCAG
AAGAGTCATACTGCCACTTC–TAMRA-3’) (Eurogentec, Liège, Belgium) and 2 μl of DNA
extract or 2 μl of HPLC water (as negative template control). Cycling conditions were as fol-
lows: 95°C for 5 min; 40 cycles of 95°C for 10 s, 58°C for 15 s and 72°C for 20 s. For the stan-
dard series, DNA concentration of the extract of S. agalactiae LMG 14694T was determined
using the Qubit1 Fluorometer (Invitrogen, Auckland, New Zealand) and the genomic concen-
tration was calculated based on the GC% content and genome size of the type strain. A tenfold
dilution standard series of S. agalactiae LMG 14694T DNA was prepared by dilution of the
DNA stock in HPLC grade water. All standard tenfold dilution series and samples were run in
duplicate. Amplification, detection and quantification were carried out using the LightCy-
cler4801 platform and the LightCycler1 480 Software Version 1.5 (Roche).
Escherichia coli qPCR
To detect E. coli in vaginal DNA extracts, an E. coli specific qPCR was carried out, using prim-
ers targeting the β-glucuronidase encoding gene uidA, previously described [24]. The qPCR
reactions were performed in a final volume of 10 μl, containing 5 μl of LightCycler 4801
SYBR Green I Master (Roche), 0.3 μM of both forward primer EcoliFW (5’-CAACGAACTGA
ACTGGCAGA-3’) and reverse primer EcoliRV (5’- CATTACGCTGCGATGGAT -3’) (Euro-
gentec) and 2 μl of DNA extract or 2 μl of HPLC water (as negative template control). Cycling
conditions were as follows: 50°C for 2 min, 95°C for 10 min; 40 cycles of 95°C for 15 s and
60°C for 1 min. A standard series (using E. coli ATCC 25922 grown on TSA + 5% sheep blood
(BD)), was constructed as described for S. agalactiae.
Candida albicans qPCR
To detect C. albicans in vaginal DNA extracts, a C. albicans specific qPCR was carried out,
using primers targeting the ITS-1 gene (adapted from [25]). The qPCR reactions were per-
formed in a final volume of 10 μl, containing 5 μl of LightCycler 4801 SYBR Green I Master
(Roche), 0.3 μM of both forward primer CA_FW (5’-CAACGAACTGAACTGGCAGA-3’)
and reverse primer CA_RV (5’- CATTACGCTGCGATGGAT -3’) (Eurogentec) and 2 μl of
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DNA extract or 2 μl of HPLC water (as negative template control). Cycling conditions were as
follows: 50°C for 2 min, 95°C for 10 min; 40 cycles of 95°C for 15 s and 60°C for 1 min. A stan-
dard series (using C. albicans ATCC 90028 grown on Sabouraud agar (BD)), was constructed
as described for S. agalactiae.
Microbiological culturing. At the local laboratories, the Amies swab was inoculated on
in-house TMBplus plates (a medium supporting growth of anaerobes and allowing assessment
of hydrogen peroxide production of strains) [26], after which the plates were incubated anaero-
bically as described previously [27]. After 48–72 h, depending on the growth, all biological
material of the culture plate was harvested using sterile cotton swabs and stored in cryovials
with 1 ml of tryptic soy broth + 5% glycerol at– 80°C until shipment. After shipment to the
ITM, bacteria from the cryovial were inoculated in commercial Lim Broth medium (BD)–a
selective enrichment medium for GBS–according to the manufacturer’s instructions (5% CO2
at 35°C for 24 hours). The latter procedure was performed only for women found to be positive
for vaginal GBS carriage by means of qPCR. DNA extracts of inoculated Lim Broth medium
was used for direct molecular capsular typing of GBS.
S. agalactiaemolecular capsular typing
To determine the GBS serotype, we used a flowchart described by [28], based on the multiplex
PCRs with primers as described by Poyart and co-workers and Imperi and co-workers [29, 30].
The multiplex PCRs were performed directly on DNA extracted from the inoculated Lim
Broth medium. The reactions were performed in a final reaction mixture of 20 μl, containing
10 μl of FastStart PCR Master Mix (Roche), 0.2 μM of each primer, and 2 μl of DNA template.
Using a Veriti 96-well thermal cycler (Applied Biosystems, Foster City, CA), the following PCR
program was run: 94°C for 5 min, 3 cycles of 45 s at 94°C, 2 min at 50°C, 1 min at 72°C, and 30
cycles of 20 s at 94°C, 1 min at 50°C and 1 min at 72°C, with a final extension at 72°C for 7
min. PCR amplification products were visualised under UV light after electrophoresis on 1%
agarose gels (30 minutes at 10 V/cm) and staining with ethidiumbromide. Twenty five control
strains (covering all GBS serotypes and provided by the Belgian Streptococcus agalactiae refer-
ence center (Dr. Pierette Melin, University of Liège, Belgium)) were used as a positive control.
Physiological parameters
Vaginal pH was measured during the speculum examination by pressing commercial pH strips
(pH Fix 3.6–6.1, Machery-Nagel) against the vaginal wall.
Detection of prostate-specific antigen (PSA), a marker for sexual intercourse within the past
24 hours [31] in vaginal swab fluid was performed using a chromatographic immune assay
(the Seratec1 PSA SemiQuant Cassette Test, Seratec, Gottingen, Germany) according to the
manufacturer’s instructions. Pregnancy was assessed by testing urine with a rapid hCG test
(QuickVue One-Step hCG Test (Kigali, Johannesburg) or Unimed First Sign hCG test (Mom-
basa)). Leucocytes and erythrocytes in urine were detected using dipsticks according to the
manufacturer’s instructions (Siemens Multistix 10 sg in Kigali, Mission1 urinalysis strips in
Mombasa, and Neotest 4 Urine Dipstick in Johannesburg).
Statistical analysis
Data were analyzed with SPSS software version 22 (SPSS Inc.). Prevalences were reported with
their 95% confidence interval. Outcomes for this analysis were vaginal GBS carriage and vagi-
nal E. coli carriage, as determined by a positive qPCR.
Independent variables considered were study site, sociodemographic characteristics, repro-
ductive health characteristics, sexual behavioural factors, vaginal practices characteristics,
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cervicovaginal signs and symptoms and microbiological characteristics. Variables were ana-
lyzed using logistic regression in univariable and multivariable ways, with p-values< 0.05 indi-
cating significance. In order not to overfit our multivariable models, variables were restricted
in proportion to the number of cases positive for GBS and E. coli, i.e. maximum one degree of
freedom per 10 cases [32]. Variables included in the models were selected as follows [33]:
firstly, only variables found to be significantly associated with GBS or E. coli carriage in univari-
able analysis were considered for inclusion the multivariate GBS or E. colimodel, respectively.
Subsequently, of correlated variables (e.g. ‘having had recent vaginal intercourse’ and a positive
PSA test), only one was kept for further consideration to avoid collinearity. The final selection
of variables was based on literature and clinical expertise/relevance. The multivariable models
were controlled for possible confounding variables and were validated with bootstrap analysis.
Ethics statement
Written information and consent forms in the local language were provided to the women or
to the Legally Authorized Representatives for their review. After the interview, the participants
were asked to express their willingness to participate in the study by signing (or thumb-print-
ing in case they were illiterate) the consent form. In case they were of minor age (age below 18
in Kenya and SA, and below 21 in Rwanda), also the parents or guardians were asked to give
consent. The study was approved by the Kenyatta National Hospital Ethical Review Commit-
tee, Kenya; the Human Research Ethics Committee (Medical), University of the Witwaters-
rand, SA; the Rwanda National Ethics Committee, Rwanda; the Institutional Review Boards of
the Institute of Tropical Medicine in Antwerp, of Ghent University, and of the University
Teaching Hospital in Antwerp, Belgium. In addition, the study was approved by the National
Council on Science and Technology in Kenya, and the National AIDS Control Commission in
Rwanda. The study is registered at the Trial Registration at the National Health Research Ethics
Council South Africa (DOH2709103223) [19].
Results
Vaginal GBS and E. coli carriage and GBS serotype distribution
Of the 430 women enrolled in the study, 424 and 421 vaginal swab DNA extracts were analysed
for the presence of GBS and E. coli, respectively. The vaginal GBS and E. coli carriage rates in
the different study groups are presented in Table 1.
The GBS serotype distribution is presented in Table 2 and Fig 1. For 12 GBS carriers, the
serotype could not be determined because samples were no longer available. Serotype distribu-
tion was largely comparable between sites. The most prevalent serotypes were Ia (27.3%), V
(27.3%), and III (22.7%) in Kenya; Ia (34.5%), V (31.0%), and IV (13.8%) in SA; and Ia (83.3%)
and II (16.7%) in Rwanda.
Univariable and multivariable analyses
Tables 3 and 4 present the univariable associations of the sociodemographics, sexual behavior,
vaginal practices, cervicovaginal signs and symptoms, and microbiological characteristics with
vaginal GBS and E. coli carriage, respectively. Because of the low prevalence, CT, NG, TV, and
syphilis were not considered for further analysis.
In our final multivariable GBS model (Table 5), BV by Nugent score remained significantly
negatively associated with GBS carriage (AOR, 0.43; 95% CI, 0.21–0.88; p = 0.022), and a posi-
tive association was observed for vaginal Candida albicans carriage (AOR, 3.25; 95% CI, 1.50–
7.06; p = 0.003), vaginal E. coli carriage (AOR, 2.01; 95% CI, 1.10–3.80; p = 0.023), recent
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vaginal intercourse (AOR, 2.63; 95% CI, 1.35–5.15; p = 0.005), and currently washing the
vagina (AOR, 2.26; 95% CI, 1.16–4.37; p = 0.016).
In our multivariable E. colimodel, an intermediate Nugent score remained significantly neg-
atively associated with vaginal E. coli carriage (AOR, 2.61; 95% CI, 1.15–5.94; p = 0.023), and a
positive association was observed with working as a FSW (AOR, 7.83; 95% CI, 2.88–21.30;
p<0.001), vaginal GBS carriage (AOR, 2.05; 95% CI, 1.09–3.83; p = 0.025), and cervical ectopy
(AOR, 1.64; 95% CI, 1.01–2.68; p = 0.046) (Table 6).
Discussion
Group B streptococci (GBS) and E. coli account for the majority of EOS cases worldwide.
Vaginal carriage of GBS and E. coli is considered a prerequisite for GBS or E. coli transmis-
sion to the neonate in GBS EOS and E. coli EOS, respectively. However, epidemiological data
of vaginal GBS and E. coli carriage, which are essential for the development and implementa-
tion of prevention strategies, are very limited in sub-Saharan Africa (SSA) [16, 17].
Table 2. Studies reporting GBS serotype distribution of (recto)vaginal isolates in SSA.
Country Year Population Ia Ib II III IV V VI VII VIII IX NT Reference
The Gambia 1994 P 19 28 6 3 38 [34]$
Malawi 2011 P, HIV+, HIV- 18.2 6.2 10.3 39.0 0.3 23.9 0.8 0.8 1.5 [35]
SA 2011 P 30.1 6.7 11.3 37.3 3.7 10.2 [36]
SA 2014 P 36.2–41.4 3.5–4.6 7.2–7.5 31.3–34.9 2.0–4.0 10.3–15.6 0.0–3.3 [37]
Kenya 2015 P, NP 27.3 22.7 27.3 13.6 4.5 4.5 This study
Rwanda 2015 NP 83.3 16.7 This study
SA 2015 P, NP 34.5 10.3 13.8 31.0 6.9 3.4 This study
Europe 2010 N/A 18.2 12.4 14.4 28.1 3.7 14.9 0.6 0.6 0.6 [38]£
US 2010 N/A 26.8 8.1 10.9 24.8 1.0 15.0 0.3 0.0 0.2 [38]£
P, pregnant; NP, non-pregnant
$determined serotypes I-VI (no differentiation between Ia and Ib); N/A, not applicable (review)
£data from meta-analysis but excluding isolates from non-sterile sites and from neonates were excluded.
doi:10.1371/journal.pone.0148052.t002
Fig 1. Distribution of GBS capsular serotypes. Left, Kenya (n = 22); middle, Rwanda (n = 6); right, South Africa (n = 29).
doi:10.1371/journal.pone.0148052.g001
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Table 3. Sociodemographic characteristics, reproductive health, sexual behavior, vaginal practices, vaginal signs & symptoms, andmicrobiolog-
ical associations with vaginal GBS carriage (univariable analysis).
n GBS+ n (%) Crude OR (95% CI) p-value*
424 69 (16.3)
Sociodemographic characteristics
City (Country)
Mombasa (Kenya) 165 27 (16.4) 0.89 (0.51–1.53) 0.665
Kigali (Rwanda) 60 6 (10.0) 0.50 (0.20–1.26) 0.142
Johannesburg (SA) 199 36 (18.1) 1 -
Age (years)
<18 58 1 (1.7) 0.07 (0.01–0.50) 0.008
18–24 148 23 (15.5) 0.71 (0.41–1.23) 0.219
>24 218 45 (20.6) 1 -
Educational level
Higher educational level£ 189 39 (20.6) 1 -
Lower educational level££ 235 30 (12.8) 0.56 (0.33–0.95) 0.030
Marital status
Never married 242 34 (14.0) 1 -
Married 148 30 (20.2) 1.55 (0.91–2.67) 0.109
Separated/divorced/widowed 34 5 (14.7) 1.06 (0.38–2.91) 0.918
Socio-economic status#
Low 106 17 (13.0) 1 -
Medium 163 31 (19.0) 1.23 (0.64–2.36) 0.533
High 155 21 (13.5) 0.82 (0.41–1.64) 0.576
Reproductive health
Pregnant
No 366 62 (16.9) 1 -
Yes 58 7 (12.1) 0.67 (0.29–1.55) 0.353
Parity
0 149 18 (12.1) 1 -
1–2 211 42 (19.9) 1.81 (1.00–3.29) 0.052
>2 64 9 (14.1) 1.19 (0.50–2.81) 0.690
Gravity
0 118 14 (11.9) 1 -
1–2 210 38 (18.1) 1.64 (0.85–3.17) 0.141
>2 96 17 (17.7) 1.60 (0.74–3.44) 0.230
Regular cycle
Yes 256 42 (16.4) 1 -
No/unknown 168 27 (16.1) 0.98 (0.58–1.66) 0.927
Menstrual cycle
No cycle 194 33 (17.0) 1 -
With cycle 230 36 (15.7) 0.91 (0.54–1.51) 0.706
Contraceptive
None 73 15 (20.5) 1 -
Condom only 108 10 (9.3) 0.40 (0.17–0.94) 0.035
Others (hormones/IUD/sterilisation/pregnant) 243 44 (18.1) 0.86 (0.44–1.65) 0.639
Currently breastfeeding
No 390 64 (16.4) 1 -
Yes 34 5 (14.7) 0.88 (0.33–2.36) 0.796
(Continued)
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Table 3. (Continued)
n GBS+ n (%) Crude OR (95% CI) p-value*
Sexual behaviour
Age at ﬁrst sexual encounter (years)
<16 80 8 (10.0) 1 -
16–18 197 36 (18.3) 2.01 (0.89–4.5) 0.093
19–21 104 16 (15.4) 1.64 (0.66–4.04) 0.286
>21 43 9 (20.9) 2.38 (0.85–6.71) 0.101
Sexually active (last 3 months)
No 55 4 (7.3) 1 -
Yes 369 65 (17.6) 2.73 (0.95–7.81) 0.062
Condom use (at last sexual encounter)@
No 229 47 (20,5) 1.75 (0.94–3.16) 0.050
Yes 140 18 (12.9) 1 -
Lifetime n° of sex partners
1 112 13 (11.6) 1 -
2–3 186 32 (17.2) 1.58 (0.79–3.16) 0,194
> 3 126 24 (19.0) 1.79 (0.86–3.71) 0,117
N° of sex partners in the last 3 months
0 25 0 (0.0) 1 -
> = 1 399 69 (17.3) N/A 0.010
Recent vaginal sex%
No 343 49 (14.3) 1 -
Yes 81 20 (24.7) 2.73 (0.95–7.81) 0.024
Sexual risk taking€
Low 167 25 (15.0) 1 -
Medium 155 30 (19.4) 1.36 (0.76–2.44) 0.297
High 102 14 (13.7) 0.90 (0.45–1.83) 0.779
Estimated frequency of sexual encounters in last 3 months@, &
0 55 4 (7.3) 1 -
< 10 times 137 18 (13.1) 1.93 (0.62–5.98) 0.255
11–30 times 129 24 (18.6) 2.91 (0.96–8.84) 0.059
> 30 times 98 23 (23.5) 3.91 (1.27–11.98) 0.017
HIV status partner@,
HIV positive 38 3 (7.9) 1 -
HIV negative 250 52 (20.8) 3.06 (0.91–10.36) 0.072
Unknown 79 10 (12.6) 1.69 (0.44–6.54) 0.447
Estimated frequency of unprotected sex in last 3 months
No sexual contacts 55 4 (7.3) 1 -
Never unprotected 104 12 (11.5) 1.66 (0.51–5.42) 0.399
< 10 times 88 14 (15.9) 2.41 (0.75–7.75) 0.139
> = 10 times 177 39 (22.0) 3.60 (1.23–10.59) 0.020
New partner (within 3 months)
No 378 60 (15.9) 1 -
Yes 46 9 (19.6) 1.29 (0.59–2.81) 0.523
Circumcision status partner@,
Circumcised 240 38 (15.8) 1 -
No/don’t know Not circumcised/don’t know 129 27 (20.9) 1.41 (0.81–2.43) 0.222
Female sex worker
(Continued)
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Table 3. (Continued)
n GBS+ n (%) Crude OR (95% CI) p-value*
Yes 30 6 (20.0) 1 -
No 394 64 (16.2) 1.03 (0.38–2.97) 0.952
Vaginal practices
Washing inside the vagina when bathing
No 176 15 (8.5) 1 -
Yes 248 54 (21.8) 2.99 (1.63–5.49) <0.001
Drying the vagina before sex
Yes 10 4 (40.0) 1 -
No 414 65 (15.7) 3.58 (0.98–13.04) 0.053
Washed inside the vagina recently (morning or evening before study visit)
No 231 28 (12.1) 1 -
Yes 193 41 (21.2) 1.96 (1.16–3.30) 0.012
Products to wash/clean/dry/tighten the vagina
None 153 13 (8.5) 1 -
Water/ﬁngers only or water/soap 211 44 (20.9) 2.84 (1.47–5.48) 0.002
Cloth 48 9 (18.8) 2.49 (0.99–6.24) 0.053
Lemon juice/detergents 12 3 (25.0) 3.59 (0.86–14.92) 0.079
Cleaning the vagina after sexual intercourse
No 227 28 (12.3) 1 -
Yes 197 41 (20.8) 1.87 (1.11–3.16) 0.019
Cervicovaginal signs and symptoms
Ectopy¶
No 226 34 (15.0) 1 -
Yes 197 34 (17.3) 1.18 (0.70–1.98) 0.536
Degree of ectopy¶
Absent 226 34 (15.0) 1 -
Small 53 8 (15.1) 1.00 (0.44–2.32) 0.993
Moderate 139 24 (17.3) 1.18 (0.67–2.09) 0.573
Large 5 2 (40.0) 3.77 (0.61–23.4) 0.155
Colposcopic ﬁndings§,¶
No 380 59 (15.5) 1 -
Yes 43 10 (23.3) 1.65 (0.77–3.53) 0.197
Cervical mucus
No 270 39 (14.4) 1 -
Mild to moderate 140 28 (20.0) 1.48 (0.87–2.53) 0.151
Abundant 14 2 (14.3) 0.99 (0.21–4.58) 0.987
Reported abnormal discharge
No 399 64 (16.0%) 1 -
Yes 25 5 (20%) 1.31 (0.47–3.61) 0.604
Vaginal discharge on speculum
No 332 52 (15.7) 1 -
Yes 92 17 (18.5) 0.82 (0.45–1.50) 0.518
Vaginal epithelial abnormalities
No 419 67 (16.0) 1 -
Yes 5 2 (40.0) 3.50 (0.57–21.36) 0.174
Cervical epithelial abnormalities
No 379 64 (16.9) 1 -
(Continued)
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Table 3. (Continued)
n GBS+ n (%) Crude OR (95% CI) p-value*
Yes 45 5 (11.1) 0.62 (0.23–1.62) 0.325
Red blood cells in urine
No 358 58 (16.2) 1 -
Yes 66 11 (16.7) 1.03 (0.51–2.10) 0.925
White blood cells in urine
No 328 56 (17.1) 1 -
Yes 96 13 (13.5) 0.76 (0.40–1.46) 0.411
Microbiological factors
BV visit 1 (Amsel criteria)
No BV 346 61 (17.6) 1 -
BV 78 8 (10.3) 0.53 (0.24–1.17) 0.116
BV (Nugent) ¶
No BV (Nugent 0–3) 217 37 (17.1) 1 -
Intermediate (Nugent 4–6) 29 6 (20.7) 1.30 (0.60–2.83) 0.507
BV (Nugent 7–10) 137 13 (9.5) 0.29 (0.12–0.70) 0.006
Reproductive tract infection (RTI)
No RTI 352 60 (17.0) 1 -
1 or more RTI 60 8 (13.3) 0.75 (0.34–1.66) 0.475
>1 RTI 12 1 (8.3) 0.44 (0.06–3.50) 0.439
Syphilis
No 415 69 (16.6) 1 -
Yes 9 0 (0.0) N/A 0.001
Chlamydia trachomatis
No 382 62 1 -
Yes 42 7 1.03 (0.44–2.43) 0.942
Neisseria gonorrhoeae
No 415 69 (16.6) 1 -
Yes 9 0 (0.0) N/A 0.001
Trichomonas vaginalis
No 390 66 (16.9) 1 -
Yes 26 3 (11.5) 0.64 (0.19–2.20) 0.478
Candida albicans (qPCR)
No 375 50 (13.3) 1 -
Yes 46 17 (37.0) 3.81 (1.95–7.44) <0.001
Escherichia coli (qPCR)
No 354 89 (25.1) 1 -
Yes 67 29 (43.3) 2.27 (1.33–3.90) 0.003
HSV-2 serology
No 276 42 (15.2%) 1 -
Yes 147 27 (18.4%) 1.25 (0.74–2.13) 0.404
Vaginal pH
< 4.4 126 15 (11.9) 1 -
4.4–5.3 240 42 (17.5) 1.57 (0.83–2.96) 0.163
5.4 and more 58 12 (20.7) 1.93 (0.84–4.44) 0.122
PSA present
No 233 31 (13.3) 1 -
Yes 181 38 (21.0) 1.73 (1.03–2.91) 0.039
(Continued)
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In this study, we aimed to present vaginal GBS and E. coli carriage rates, GBS serotype dis-
tribution and define risk factors for carriage in populations from three SSA countries.
Vaginal GBS and E. coli carriage rates
We found a vaginal GBS carriage rate of 20.2% and 23.2% in the Kenyan and South African ref-
erence groups (adult, non-pregant, HIV-negative women at average risk of HIV), respectively.
Compared to these reference groups, adolescents in our study were found to have lower GBS
carriage rates: 3.6% of the Kenyan and 0% of the SA adolescents carried GBS vaginally. Other
studies report conflicting associations between age and vaginal GBS carriage [39–47]. All of
these studies (except for [44]) report on pregnant women. Interestingly, when we compare dif-
ferent age groups (< 18 years, 18–24 years,> 24 years) in our Kenyan and SA population, we
see no age-group dependent GBS colonization in the pregnant women. However, we do see a
statistically significant age-group dependent GBS association in the non-pregnant women,
with the lowest and the highest GBS carrier rates in the youngest and the oldest age groups,
respectively (Pearson Chi-Square test, data not shown).
The pregnant women in our study population had vaginal GBS carriage rates of 14.3% and
10.0% in Kenya and SA, respectively. This is lower then most other studies reporting (recto)
vaginal GBS carriage rates in SSA (see Table 7). Although the CDC recommends rectovaginal
sampling for detection of GBS in pregnant women, we only swabbed vaginally, to be able to
study the interaction of GBS with the vaginal immune system and vaginal microbiome (to be
published). This vaginal sampling may (partly) explain the lower GBS carriage rates found by
us, as rectovaginal sampling has been shown to yield higher GBS recovery rates compared to
vaginal sampling alone [48, 49]. Furthermore, in contrast to other studies (listed in Table 7)
using culturing techniques, we used qPCR without prior enrichment step to detect GBS.
Table 3. (Continued)
n GBS+ n (%) Crude OR (95% CI) p-value*
Systemic antibiotics visit 1
No 341 62 (18.1) 1 -
Yes 83 7 (8.4) 0.41 (0.18–0.94) 0.036
Systemic antibiotics screening visit
No 391 68 (17.4) 1 -
Yes 33 1 (3.0) 0.15 (0.02–1.11) 0.063
*bold: signiﬁcant at the 5% level
£completed secondary school, or post-secondary school
££Primary school (completed or not), secondary school but not completed
#Socio-economic-status was constructed from total income, type of housing, type of toilet
@with partners within three months prior to enrolment
&missing data for 5
%sex morning or evening before visit &
€low risk: 1 or no partners in last year and did not have any partner (in the last 3 months) with multiple partners and age ﬁrst sex at least 15 years; medium
risk: 2 partners last year or had at least one sexual partner (in the last 3 months) who had multiple partners; high risk: sex worker or at least 3 partners last
year or at had at least one sexual partner with HIV in the last 3 months or age ﬁrst sex less than 15 years; N/A, no odds ratio due to no cases in one
category
¶data missing for 1 (ectopy, colposcopic ﬁndings, HSV-2 serology), 3 (C. albicans, E. coli), 8 (T. vaginalis), 41 (BV Nugent, unreadable slides)
§petechiae (6 GBS cases/20), abrasion (2 GBS cases/5), erythema (1 GBS case/10), laceration (1 GBS case/4); BV, bacterial vaginosis; IUD, intrauterine
device.
doi:10.1371/journal.pone.0148052.t003
Vaginal GBS and Escherichia coliCarriage in Sub-Saharan Africa, Prevalences and Risk Factors
PLOS ONE | DOI:10.1371/journal.pone.0148052 January 26, 2016 13 / 30
Table 4. Sociodemographic characteristics, reproductive health, sexual behavior, vaginal practices, vaginal signs & symptoms, andmicrobiolog-
ical associations with vaginal E. coli carriage (univariable analysis).
n E. coli + n (%) Crude OR (95% CI) p-value*
421 118 (28.0)
Sociodemographic characteristics
City (Country)
Mombasa (Kenya) 164 39 (23.6) 0.87 (0.54–1.41) 0.569
Kigali (Rwanda) 60 27 (45.0) 2.28 (1.25–4.15) 0.007
Johannesburg (SA) 197 52 (26.5) 1 -
Age (years)
<18 58 12 (20.7) 0.73 (0.36–1.47) 0.376
18–24 147 49 (33.3) 1.40 (0.88–2.20) 0.154
>24 216 57 (26.4) 1 -
Educational level
Higher educational level£ 187 56 (29.9) 1 -
Lower educational level££ 234 62 (26.5) 0.84 (0.55–1.29) 0.434
Marital status
Never married 240 71 (29.6) 1 -
Married 147 37 (25.2) 0.80 (0.50–1.27) 0.348
Separated/divorced/widowed 34 10 (29.4) 0.99 (0.45–2.18) 0.984
Socio-economic status#
Low 106 27 (25.5) 1 -
Medium 163 46 (28.2) 1.15 (0.66–2.00) 0.620
High 152 45 (29.6) 1.23 (0.70–2.15) 0.467
Reproductive health
Pregnant
No 363 104 (28.7) 1 -
Yes 58 14 (24.1) 0.79 (0.42–1.51) 0.478
Parity
0 149 35 (23.5) 1 -
1–2 209 62 (29.7) 1.37 (0.85–2.22) 0.196
>2 63 21 (33.3) 1.63 (0.85–3.11) 0.139
Gravity
0 118 25 (21.2) 1 -
1–2 208 63 (30.3) 1.62 (0.95–2.75) 0.077
>2 95 30 (31.6) 1.72 (0.93–3.19) 0.087
Regular cycle
Yes 254 65 (25.6) 1 -
No/unknown 167 54 (33.3) 1.42 (0.92–2.18) 0.111
Menstrual cycle
No cycle 194 58 (29.9) 1 -
With cycle 227 60 (26.4) 0.84 (0.55–1.29) 0.430
Contraceptive
None 72 20 (27.8) 1 -
Condom only 106 28 (26.4) 0.93 (0.48–1.83) 0.841
Others (hormones/IUD/sterilisation/pregnant) 243 70 (28.8) 1.05 (0.59–1.89) 0.865
Currently breastfeeding
No 387 106 (27.4) 1 -
Yes 34 12 (35.3) 1.45 (0.69–3.03) 0.327
(Continued)
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Table 4. (Continued)
n E. coli + n (%) Crude OR (95% CI) p-value*
Sexual behaviour
Age at ﬁrst sexual encounter (years)
<16 79 29 (36.7) 1 -
16–18 197 52 (26.4) 0.62 (0.35–1.08) 0.090
19–21 103 26 (25.2) 0.58 (0.31–1.10) 0.096
>21 42 11 (26.2) 0.61 (0.27–1.40) 0.224
Sexually active (last 3 months)
No 55 16 (29.1) 1 -
Yes 366 102 (27.9) 0.94 (0.50–1.76) 0.851
Condom use (at last sexual encounter)
No 283 68 (24.0) 1.80 (1.16–2.79) 0.009
Yes 138 50 (36.2) 1 -
Lifetime n° of sex partners
1 110 28 (25.5) 1 -
2–3 185 42 (22.7) 0.86 (0.50–1.49) 0.591
> 3 126 48 (38.1) 1.80 (1.03–3.15) 0.039
N° of sex partners in the last 3 months
0 25 6 (24.0) 1 -
> = 1 396 112 (28.3) 1.25 (0.49–3.21) 0.644
Recent vaginal sex%
No 340 91 (26.8) 1 -
Yes 81 27 (33.3) 1.37 (0.81–2.30) 0.238
Sexual risk taking€
Low 167 44 (26.3) 1 -
Medium 152 37 (22.4) 0.90 (0.54–1.49) 0.681
High 102 37 (36.3) 1.59 (0.94–2.71) 0.086
Estimated frequency of sexual encounters in last 3 months@, &
0 55 16 (29.1) 1 -
< 10 times 135 31 (23.0) 0.73 (0.36–1.47) 0.376
11–30 times 128 43 (33.6) 1.23 (0.62–2.45) 0.550
> 30 times 98 27 (27.6) 0.93 (0.45–1.93) 0.839
HIV status partner@
HIV positive 38 11 (28.9) 1 -
HIV negative 247 63 (25.5) 0.84 (0.39–1.79) 0.653
Unknown 79 28 (35.4) 1.35 (0.58–3.12) 0.486
Estimated frequency of unprotected sex in last 3 months
No sexual contacts 55 16 (29.1) 1 -
Never unprotected 102 34 (33.3) 1.22 (0.60–2.49) 0.586
< 10 times 87 19 (21.8) 0.68 (0.31–1.48) 0.330
> = 10 times 177 49 (27.7) 0.93 (0.48–1.82) 0.839
New partner (within 3 months)
No 375 96 (25.6) 1 -
Yes 46 22 (47.8) 2,66 (1.43–4.97) 0.002
Circumcision status partner@
Circumcised 238 62 (26.1) 1 -
Not circumcised/don’t know 128 40 (31.3) 1.29 (0.80–2.07) 0.291
Female sex worker
(Continued)
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Table 4. (Continued)
n E. coli + n (%) Crude OR (95% CI) p-value*
No 391 97 (24.8) 1 -
Yes 30 21 (70.0) 7.07 (3.13–15.96) <0.001
Vaginal practices
Washing inside the vagina when bathing
No 175 44 (25.1) 1 -
Yes 246 74 (30.1) 1.28 (0.83–1.98) 0.267
Drying the vagina before sex
No 411 114 (27.3) 1 -
Yes 10 4 (40.0) 1.74 (0.48–6.27) 0.399
Washed inside the vagina recently (morning or evening before study visit)
No 229 64 (27.9) 1 -
Yes 192 54 (28.1) 1.01 (0.66–1.55) 0.968
Products to wash/clean/dry/tighten the vagina
None 153 40 (26.1) 1 -
Water/ﬁngers only or water/soap 210 59 (28.1) 1.10 (0.69–1.77) 0.680
Cloth 46 16 (34.8) 1.51 (0.74–3.05) 0.255
Lemon juice/detergents 12 3 (25.0) 0.94 (0.24–3.65) 0.931
Cleaning the vagina after sexual intercourse
No 226 61 (27.0) 1 -
Yes 195 57 (29.2) 1.12 (0.73–1.71) 0.610
Cervicovaginal signs and symptoms
Ectopy¶
No 224 49 (21.9) 1 -
Yes 196 69 (35.2) 1.94 (1.26–2.99) 0.003
Degree of ectopy¶
Absent 224 49 (21.9) 1 -
Small 52 22 (42.3) 2.62 (1.39–4.94) 0.003
Moderate 139 46 (33.1) 1.77 (1.10–2.84) 0.019
Large 5 1 (20.0) 0.89 (0.10–8.17) 0.920
Colposcopic ﬁndings§, ¶
No 377 102 (27.1) 1 -
Yes 43 16 (37.2) 1.60 (0.83–3.09) 0.163
Cervical mucus
No 269 67 (24.9) 1 -
Mild to moderate 138 47 (34.1) 1.56 (1.00–2.44) 0.052
Abundant 14 4 (28.6) 1.21 (0.37–3.97) 0.758
Reported abnormal discharge
No 396 112 (28.3) 1 -
Yes 25 6 (24.0) 0.80 (0.31–2.06) 0.644
Vaginal discharge on speculum
No 331 85 (25.7) 1 -
Yes 90 33 (36.7) 1.68 (1.02–2.75) 0.041
Vaginal epithelial abnormalities
No 416 116 (27.9) 1 -
Yes 5 2 (40.0) 1.72 (0.28–10.45) 0.554
Cervical epithelial abnormalities
No 377 105 (27.9) 1 -
(Continued)
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Table 4. (Continued)
n E. coli + n (%) Crude OR (95% CI) p-value*
Yes 44 13 (29.5) 1.09 (0.55–2.16) 0.813
Red blood cells in urine
No 355 101 (28.5) 1 -
Yes 66 17 (25.8) 0.87 (0.48–1.59) 0.655
White blood cells in urine
No 325 81 (24.9) 1 -
Yes 96 37 (38.5) 1.89 (1.17–3.06) 0.010
Microbiological factors
BV visit 1 (Amsel criteria)
No BV 344 99 (28.8) 1 -
BV 77 19 (24.7) 0.81 (0.46–1.43) 0.469
BV visit 1 (Nugent) ¶
No BV (Nugent 0–3) 217 60 (27.6) 1 -
Intermediate (Nugent 4–6) 29 15 (51.7) 2.80 (1.28–6.16) 0.010
BV (Nugent 7–10) 137 33 (24.1) 0.83 (0.51–1.36) 0.459
GBS
No 354 89 (25.1) 1 -
Yes 67 29 (43.3) 2.27 (1.33–3.90) 0.003
Reproductive tract infection (RTI)
No RTI 349 96 (27.5) 1 -
1 or more RTI 60 19 (31.7) 1.22 (0.68–2.21) 0.508
>1 RTI 12 3 (25.0) 0.88 (0.23–3.31) 0.848
Syphilis
No 412 117 (28.4) 1 -
Yes 9 1 (11.1) 0.32 (0.04–2.55) 0.279
Chlamydia trachomatis
No 379 107 (28.2) 1 -
Yes 42 11 (26.2) 0.90 (0.44–1.86) 0.780
Neisseria gonorrhoeae
No 412 114 (27.7) 1 -
Yes 9 4 (44.4) 2.09 (0.55–7.93) 0.278
Trichomonas vaginalis¶
No 387 105 (27.1) 1 -
Yes 26 11 (42.3) 1.97 (0.88–4.43) 0.101
Candida albicans (qPCR)
No 375 102 (27.2) 1 -
Yes 46 16 (34.8) 1.43 (0.75–2.73) 0.282
HSV-2 serology¶
No 274 80 (29.2) 1 -
Yes 146 38 (26.0) 0.85 (0.54–1.34) 0.492
Vaginal pH
< 4.4 125 34 (27.2) 1 -
4.4–5.3 237 65 (27.4) 1.01 (0.62–1.65) 0.963
5.4 and more 58 19 (32.8) 1.30 (0.66–2.56) 0.441
PSA present
No 231 69 (29.9) 1 -
Yes 180 48 (26.7) 0.85 (0.55–1.32) 0.475
(Continued)
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Table 4. (Continued)
n E. coli + n (%) Crude OR (95% CI) p-value*
Systemic antibiotics visit 1
No 338 98 (29.0) 1 -
Yes 83 20 (24.0) 0.78 (0.45–2.36) 0.374
Systemic antibiotics screening visit
No 388 111 (28.6) 1 -
Yes 33 7 (21.2) 0.67 (0.28–1.59) 0.366
*Bold: signiﬁcant at the 5% level
£completed secondary school, or post-secondary school
££Primary school (completed or not), secondary school but not completed
#Socio-economic-status was constructed from total income, type of housing, type of toilet
@with partners within three months prior to enrolment
&missing data for 5
%sex morning or evening before visit
€low risk: 1 or no partners in last year and did not have any partner (in the last 3 months) with multiple partners and age ﬁrst sex at least 15 years; medium
risk: 2 partners last year or had at least one sexual partner (in the last 3 months) who had multiple partners; high risk: sex worker or at least 3 partners last
year or at had at least one sexual partner with HIV in the last 3 months or age ﬁrst sex less than 15 years; N/A, no odds ratio due to no cases in one
category
¶data missing for 1 (ectopy, colposcopic ﬁndings, HSV-2 serology), 8 (T. vaginalis), 38 (BV Nugent, unreadable slides)
§petechiae (6 E. coli cases/20), abrasion (2 E. coli cases/5), erythema (3 E. coli cases/10), laceration (2 E. coli cases/4), ulcer (2 E. coli cases/6),
ecchymosis (2 E. coli cases/6); BV, bacterial vaginosis.
doi:10.1371/journal.pone.0148052.t004
Table 5. Multivariable associations with vaginal GBS carriage.
n GBS+ (%) adjusted OR (95% CI) p-value$
424 69 (16.3)
Recent vaginal sex%
No 343 49 (14.3) 1 -
Yes 81 20 (24.7) 2.63 (1.35–5.15) 0.005
Washing inside the vagina#
No 176 15 (8.5) 1 -
Yes 248 54 (21.8) 2.26 (1.16–4.37) 0.016
BV (Nugent)¶
No BV (Nugent 0–3) 217 37 (17.1) 1 -
Intermediate (Nugent 4–6) 29 6 (20.7) 0.93 (0.33–2.64) 0.898
BV (Nugent 7–10) 137 13 (9.5) 0.43 (0.21–0.88) 0.022
Candida albicans (qPCR)¶
No 375 50 (13.3) 1 -
Yes 46 17 (37.0) 3.25 (1.50–7.06) 0.003
Escherichia coli ¶
No 303 38 (12.5) 1 -
Yes 118 29 (24.6) 2.01 (1.10–3.80) 0.023
$bold, signiﬁcant at the 5% level
#when having shower or bath
%morning or evening before study visit
¶data missing for 3 (C. albicans, E. coli), 41 (BV, unreadable slides).
doi:10.1371/journal.pone.0148052.t005
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Although the CDC allows PCR for the detection of GBS (albeit recommending an enrichment
step), this difference with other studies probably does not account (or to a lesser extent) for the
lower rates found by us, as PCR (even without an enrichment step) has been shown to be more
Table 6. Multivariable associations with vaginal E. coli carriage.
n E. coli + (%) adjusted OR (95% CI) p-value$
421 118 (25.2)
Condom use (at last sexual encounter)
No 283 68 (24.0) 1.53 (0.92–2.56) 0.104
Yes 138 50 (36.2) 1.0 -
Female sex worker
No 391 97 (24.8) 1 -
Yes 30 21 (70.0) 7.83 (2.88–21.30) <0.001
Ectopy ¶
No 224 49 (21.9) 1 -
Yes 196 69 (35.2) 1.64 (1.01–2.68) 0.046
Vaginal discharge on speculum
No 331 85 (25.7) 1 -
Yes 90 33 (36.7) 1.63 (0.92–2.88) 0.095
BV (Nugent)¶
No BV (Nugent 0–3) 217 60 (27.6) 1 -
Intermediate (Nugent 4–6) 29 15 (51.7) 2.61 (1.15–5.94) 0.023
BV (Nugent 7–10) 137 33 (24.1) 0.66 (0.38–1.15) 0.140
GBS
No 354 89 (25.1) 1 -
Yes 67 29 (43.3) 2.05 (1.09–3.83) 0.025
$bold, signiﬁcant at the 5% level
¶data missing for 1 (ectopy), 38 (BV, unreadable slides).
doi:10.1371/journal.pone.0148052.t006
Table 7. Studies reporting (recto)vaginal GBS carriage rates in SSA.
Country Year n Population % GBS Sample Detection Reference
Nigeria 1980 588 P, L 19 V SB+C [55]
Nigeria 1983 225 P 20 V SB+C [56]
Zimbabwe 1990 89 P 31 V SB+C [57]
Togo 1991 106 P 4 V, R SB+C [58]
Gambia 1994 136 P 22 V, R SB+C [34]
Malawi 2005 97 P 16.5 V, R SA [59]
Mozambique 2008 113 P 1.8 V, R SB+C [60]
Tanzania 2009 300 P 23.0 V, R SB+C [54]
Zimbabwe 2010 780 P 47, 24, 21# V, R SB+C [61]
Malawi 2011 1840 P, HIV+ and HIV- 21.2 V, R SB+C [35]
South Africa 2014 661, 621, 595, 521$ P 33.0, 32.7, 28.7, 28.4$ V, R SA [37]
DR Congo 2015 509 P 20.2 V SA [62]
L, women in labor; NP, non-pregnant women; P, pregnant women; V, vaginal swab; R, rectal swab; SB+C, selective broth and culturing; SA, selective
agar
#week 20, 26, and delivery, respectively
$week 20–25, week 26–30, week 31–35, and week 37+, respectively.
doi:10.1371/journal.pone.0148052.t007
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sensitive than culture [14, 50–53]. A further difference with other studies regards the fact that
the pregnant women in our study were up to 14 weeks of gestation, while the other studies
listed in Table 7 sampled pregnant women at 35–37 weeks of gestation, which also may account
for differences, as some authors have reported on varying GBS rates during pregnancy [45].
In the group of HIV positive women, we did not observe any GBS carriers, which is proba-
bly explained by the fact that most of the HIV positive women (26/30) received prophylactic
cotrimoxazole, which is largely effective against GBS [54].
Our reference groups from Kenya and SA had vaginal E. coli carriage rates of 25.0% and
27.1%, respectively. Compared to other studies from SSA reporting vaginal carriage of E. coli,
these prevalences are higher than the ones reported by Karou and coworkers (2012) and
Ekwempu and coworkers (1981), lower than the ones reported by Schellenberg and coworkers
(2011) and Cutland and coworkers (2012), and comparable with the prevalence reported by
Sagna and coworkers (2010) (See Table 8)[63–67]. Vaginal E. coli carriage rates in Asia,
Europe, North and South America appear lower. Different study populations, sampling and
detection techniques might account for these differences.
Compared to the reference group in Kenya, pregnant women had a lower prevalence of vag-
inal E. coli carriage; compared to the reference group in SA, adolescent women had a lower
prevalence of E. coli carriage. The FSW study group in Kigali had a very high prevalence of E.
coli carriage, i.e. 70%, and will be discussed below (risk factors).
To our knowledge, this is the first study to determine simultaneously the vaginal GBS and E.
coli carriage rates in SSA populations using qPCR, known to be more sensitive than culture-
based techniques. Moreover, vaginal carriage rates of GBS in Kenya and Rwanda and E. coli in
Rwanda have not yet been described.
Risk factors for vaginal E. coli and GBS carriage
The presence of vaginal C. albicans, recent vaginal intercourse, working as a FSW, an interme-
diate vaginal microbiome, BV, washing the vagina and cervical ectopy were independent risk
factors for vaginal GBS or E. coli colonization.
Women carrying C. albicans were 3.6 times more likely also to carry GBS. Three US based
studies have shown this same significantly positive association between GBS and Candida or
yeast [40, 88, 89].
Intravaginal practices, like e.g. cleaning inside the vagina beyond the introitus or insertion
of substances into the vagina to dry or tighten the vagina, are common in Africa and are associ-
ated with adverse outcomes including increased risk for BV and for sexually transmitted infec-
tions [90]. Our model showed that washing inside the vagina was an independent risk factor
for vaginal GBS carriage: women were twice as likely to be colonized with GBS compared to
women not washing inside the vagina. A study by van de Wijgert and coworkers [91] showed
that women using substances other than plain water to finger-clean or wipe inside the vagina
had a GBS prevalence of 26.3% (n = 99), whereas women not engaging in these practices had a
GBS prevalence of 14.7% (n = 70). However, their findings did not reach significance, most
probably because of the smaller sample size (169 women compared to 424 women in our
study).
Women who had recent vaginal sex (the morning or evening before the study visit) were
more than twice as likely to carry GBS vaginally than women who did not. Accordingly, a posi-
tive PSA test was also significantly correlated with GBS carriage. GBS is generally not consid-
ered an STI, and the influence of sexual behavior on vaginal GBS carriage or acquisition is a
matter of debate [92–94]. Based on published literature and our own data, we hypothesize that
sexual activity might lead to a brief temporal GBS colonization of the vagina. This hypothesis is
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Table 8. Studies reporting (recto)vaginal E. coli carriage rates.
Country Year n Population % E. coli Sample Detection Reference
Africa (pooled prevalence 36.0% (2846/7912); range 9.1–46.5%)
Burkina Faso 2010 156 HIV+ 28.4 V C [67]
Burkina Faso 2012 2000 S 16.7 V C [63]
Kenya 2011 44 HIV+, HIV-, HESN 40.1 V cpn60 [65]
Nigeria 1981 187 L 9.1 C C [64]
SA 2012 1347 P, HIV+ 42.3 V C [66]
SA 2012 3752 P, HIV- 46.5 V C [66]
Asia (pooled prevalence 5.3% (163/3072); range 0–25.8%)
Iraq 2011 90 S, NP 16.2 V C [68]
Iraq 2011 20 S, P 25.8 V C [68]
Iran 2014 85 S, P 18.0 V C [69]
Japan 2002 2575 NP, P 3.4 V C [70]
Pakistan 2012 100 HC 28 V C [71]
Pakistan 2012 100 H 6 V C [71]
Turkey 2007 34 IUD 14.7 V C [72]
Turkey 2007 34 HC 2.9 V C [72]
Turkey 2007 34 H 0.0 V C [72]
Europe (pooled prevalence 13.4% (670/4980); range 3.1–51.2%)
Croatia 2011 114 IUD 25.5 V C [73]
Croatia 2011 122 H 8.2 V C [73]
Denmark 2014 668 P 11.7 V C [74]
Germany 2007 166 H 16.3, 51.2, 25.9* V C [75]
Greece 2008 1632 S 3.1 V C [76]
Lithuania 2012 970 P 19.9 V, R C [77]
Spain 2002 623 P 27.0 V C [78]
Spain 2011 321 P 15 E, V C [79]
Spain 2011 327 NP 12 E, V C [79]
Sweden 2008 37 H 5.4 V C [80]
North America (pooled prevalence 12.7% (430/3373); range 0–29.5%)
Canada 1983 495 H 12.3 V C [81]
US 1997 2646 P 13.0 V C [6]
US 2001 44 H 18.2, 9.1, 29.5, 6.8, 6.8 # V C [82]
US 2005 20 H 0 V 16S [83]
US 2012 70 P 10 V C [84]
US 2012 35 NP 23 V C [84]
US 2013 47 P 2.1, 2.2, 5.6, 8.3£ V C [85]
US 2013 16 NP 6.3, 0, 12.5, 20 V C [85]
South America (pooled prevalence 19.7% (135/684); range 14.3–23.0%)
Argentina 2013 259 P 14.3 V C [86]
Chile 2009 425 S 23.0 V C [87]
The electronic bibliographic database PubMed was searched for articles using the search terms ‘(Escherichia) AND (coli) AND (vaginal)’ with no date or
language restriction. Studies were included if the number of vaginal E. coli carriers and the total number of individuals tested were reported; studies were
excluded if women were not of childbearing age. 16S, deep sequencing of the 16S rRNA gene; cpn60, deep sequencing of the cpn60 gene; C,
conventional culturing and identiﬁcation; E, endocervial swab; FSW, female sex workers; H, healthy women; HC, women using hormonal contraception;
HESN, HIV exposed seronegative women; IUD, women using an intrauterine device as contraception; L, women in labor; NP, non-pregnant women; P,
pregnant women; Q, qPCR; R, rectal swab; S, women with vaginal symptoms or clinical diagnosis of infection; V, vaginal swab
*pre, mid, post cycle, respectively
# visit 1at 1 month before visit 2 and 19–24 days after cycle, 1–2 days before intercourse, 8-12h after intercourse, 3–4 days after intercourse, 5–6 days
after intercourse
£ <14weeks, between 14–28 weeks, >28weeks, postpartum.
doi:10.1371/journal.pone.0148052.t008
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strengthened by a recent longitudinal deep-sequencing study of the vaginal microbiome, where
25 women were sampled on a daily basis over a 10 week period, revealing an average of 0.39
GBS episodes per week and an average GBS episode of 2.8 days (Fig 1 and additional file 4 in
[95]), contrasting with earlier studies—where sampling occurred every 3 weeks—that report
average GBS episodes of 13.7 weeks [96]. The brief colonization might explain why we and
other authors find parameters such as ‘age of first sexual intercourse’ not to be associated with
GBS carriage (they do not cover the recent aspect), while parameters such as ‘high frequency of
intercourse during last month’ (as a consequence, a higher chance of also having had recent
intercourse) do correlate. Taken together, GBS should be considered as a potentially patho-
genic micro-organism that can be sexually transmitted and whose vaginal presence can be
enhanced by sexual activity.
Cervical ectopy was an independent risk factor for vaginal E. coli carriage, 21.9% of women
without cervical ectopy were E. coli carriers as opposed to 35.2% of women with cervical
ectopy. Cervical ectopy has been associated with CT [97], HPV [98] and an increased suscepti-
bility to HIV infection [99]. Although we could not determine the cause-effect relation of this
association, it seems biologically plausible that a niche is created by the glandular columnar
epithelium of women with cervical ectopy that somehow—directly or indirectly—favors the
colonization by E. coli. Some studies have e.g. related cervical ectopy with a reduced cell-medi-
ated or changed humoral immunity [21, 100].
Working as a FSW was an independent risk factor for vaginal E. coli carriage. We could not
explain this by any of the sexual behavioural or other parameters presented in Table 4. In our
study, none of the participants, including the female sex workers, reported having had anal
intercourse during the last 3 months. These percentages probably are underestimates, since
stigma associated with anal intercourse often leads to reduced reporting [101]. Furthermore,
Ghanem and coworkers [102] showed that regarding anal intercourse, significantly more
women reported to engage in these practices when asked by means of computer assisted self
interviews compared to face-to-face interviews, which was used in our study. It is not unlikely
that FSW engage more in anal intercourse, compared to the general population, and that in
our FSW population, vaginal contamination with E. coli is higher by transfer of (peri)anal bac-
teria during anal/vaginal intercourse. Other studies from East-Africa report anal intercourse
prevalences in FSW of up to 40.8% [103]. Interestingly, anal intercourse during pregnancy has
been reported as a significant risk factor for neonatal E. coli colonization [77].
Besides above-mentioned risk factors for GBS or E. coli carriage, we show for the first time
that colonization with GBS and E. coli, the leading causes of EOS, are positively associated.
Abovementioned risk factors can be translated and implemented into strategies that aim to
reduce the maternal carriage of GBS and E. coli. First, behavioral change by advocating absti-
nence from sexual intercourse and vaginal washing during late pregnancy, e.g. via counseling
in family planning facilities, could help to reduce the risk of maternal GBS and E. coli coloniza-
tion in resource-poor settings. Second, the extension of GBS screening with screening for C.
albicans and E. coli–risk factors for vaginal GBS carriage–should be further investigated. Fur-
thermore, the screening for E. coli itself also merits further investigation because of its role as a
major EOS causative agent for which currently no prevention measures are taken, nor in low-
income, nor in high-income countries [104]. In this context, the presence of cervical ectopy–a
risk factor for vaginal E. coli carriage–should be further investigated.
GBS serotype distribution
As IAP is not effective against LOS and culture-based screening and administration of costly
intravenous antibiotics might not be feasible in most low-income countries, an alternative and
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long-term solution lies in the development of effective GBS vaccines, that however would not
cover for other micro-organisms causing EOS. As most GBS vaccines under development aim
at eliciting protective antibodies against capsular polysaccharides, the principal difficulty in
developing globally effective GBS vaccines is the existence of several serotypes with different
geographical distributions. In our study, the most prevalent GBS serotypes were Ia (27.3%), V
(27.3%) and III (22.7%) in Kenya; Ia (34.5%), V (31.0%), and IV (13.8%) in SA; and Ia (83.3%)
and II (16.7%) in Rwanda. Only few other studies have documented vaginal GBS serotype dis-
tribution in Africa and these are largely in line with our findings (Table 4 and Fig 1).
Interestingly, compared to the low prevalences in Europe and the US, we found relatively
high prevalences of serotypes IV, VI, VII–shown for the first time in sub-Saharan Africa—and
VIII in the Kenyan and South African population (VI, 13.6%; VII, 4.5%; VIII 4.5% in Kenya,
and IV, 13.8%; VI, 6.9%; VIII, 3.4% in SA) (Table 4). In contrast, we did not detect any serotype
Ib, which has, according to a recent meta-analysis, a prevalence of 8.1% in the US and 12.4% in
Europe [38].
Differences in serotype distribution between our study and other studies (Table 4) might be
explained by differences in study populations, most studies listed in Table 4 typed strains iso-
lated from pregnant women whereas most of our GBS strains were isolated from non-pregnant
women. Methodological differences might also contribute. Many GBS capsular polysaccharide
typing methods have been described, with the most commonly used method being a serological
test, used by all studies listed in Table 4, except our study. We used a molecular capsular typing
method, developed and applied by European (reference) laboratories [105, 106]. Brigtsen and
coworkers (2015) compared capsular typing of 426 GBS strains by a conventional latex aggluti-
nation test with PCR, and found that a substantial proportion of the strains were non-typeable
by serotyping, but typeable by genotyping, and that an agreement between serotyping and gen-
otyping was shown in 71.1% (of the isolates that were typeable by both methods) [107]. More-
over, we used a molecular technique directly on DNA extracts from vaginal swabs (and not on
DNA extracts from isolates), which could lead to the detection of certain serotypes that would
not have been isolated by culture.
Currently, there are two candidate vaccines in phase II clinical trials, i.e. a trivalent vaccine
targeting serotypes Ia, Ib, and III, and a conjugate vaccine targeting serotype III (www.
clinicaltrials.gov). In theory, the first vaccine could cover for 50.0%, 83.3% and 44.8% of vaginal
GBS cases in our Mombasa, Kigali and Johannesburg population, respectively, but only a
minority of women would be protected by the conjugate vaccine (22.7%, 0% and 10.3%,
respectively).
GBS, E. coli and the vaginal microbiome
Our results show that vaginal GBS and E. coli carriage were significantly associated with distur-
bances of the vaginal microbiome: compared to women with a normal vaginal microbiome,
women with an intermediate vaginal microbiome were 2.61 times more likely to carry E. coli,
whereas women with BV were 2.33 less likely to carry GBS. The latter finding is in accordance
a study of Hillier and coworkers [108], reporting a significant negative association between
GBS carriage and BV by Nugent scoring, studying 7,918 pregnant women. Two other studies
did not confirm these findings [94, 109]. In depth analysis of abovementioned interdependen-
cies of GBS, E. coli, C. albicans, BV and the vaginal microbiome will be published elsewhere.
Our study was limited by the fact that we used vaginal sampling instead of rectovaginal sam-
pling for the detection of GBS (as recommended by the CDC), which has been shown to have
higher recovery rates for GBS. Furthermore, we did not use a selective broth enrichment prior
to PCR, as recommended by the CDC. In our study, pregnant women were up to 14 weeks of
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gestation, and were not sampled at 35–37 weeks’ gestation as recommended by the CDC,
which could have biased our results. Our study was further limited by the rather small sample
size of our Rwanda study population.
In conclusion, vaginal GBS carriage rate and serotype distribution were similar to high-
income countries, except for the higher prevalence of serotypes VI, VII and VIII. E. coli carriage
rate was higher compared to high-income countries. We identified risk factors for GBS or E.
coli carriage, ie. recent sexual intercourse, vaginal washing, C. albicans colonization and pres-
ence of cervical ectopy, that can be implemented in strategies to reduce maternal colonization.
Immunoprophylaxis with current phase II candidate GBS vaccines would not protect the
majority of women against vaginal GBS carriage in our study population. The most important
causative agents of EOS, GBS and E. coli, both associated with disturbances of the vaginal
microbiome, are positively associated.
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